Skip to main content

Reed John C's Form 4 filing

Johnson & Johnson (JNJ) · filed Feb 18, 2026

Accession no.
0000200406-26-000039
Filed
Feb 18, 2026
Trade date
Feb 15-17, 2026
Filing delay
3 days
Rule 10b5-1 plan
Not checked

This filing lists 9 non-derivative transactions and 6 derivative transactions. Open-market sales total $13.1M. It was filed 3 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Reed John CCIK 0001181561Officer (EVP, Innovative Medicine, R&D)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 15, 2026Common StockMOption exerciseAcquired+1,349$0.00F1$012,007Direct
Feb 15, 2026Common StockFTax withholdingDisposed−385$243.45−$93,728.2511,622Direct
Feb 15, 2026Common StockMOption exerciseAcquired+1,847$0.00F3$013,469Direct
Feb 15, 2026Common StockFTax withholdingDisposed−528$243.45−$128,541.612,941Direct
Feb 17, 2026Common StockMOption exerciseAcquired+21,721$157.92+$3,430,180.3234,662Direct
Feb 17, 2026Common StockSSaleDisposed−21,721$243.00−$5,278,20312,941Direct
Feb 17, 2026Common StockMOption exerciseAcquired+29,927$156.15+$4,673,101.0542,868Direct
Feb 17, 2026Common StockSSaleDisposed−29,927$243.00−$7,272,26112,941Direct
Feb 17, 2026Common StockSSaleDisposed−2,283$243.00−$554,76910,658Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 15, 2026Common StockMOption exerciseDisposed−1,349$0.00$01,349Direct
Feb 15, 2026Common StockMOption exerciseDisposed−1,847$0.00$03,692Direct
Feb 15, 2026Common StockAGrant or awardAcquired+49,382$0.00$049,382Direct
Feb 15, 2026Common StockAGrant or awardAcquired+3,546$0.00$03,546Direct
Feb 17, 2026Common StockMOption exerciseDisposed−21,721$0.00$021,721Direct
Feb 17, 2026Common StockMOption exerciseDisposed−29,927$0.00$059,854Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2024 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSU convert into shares of Common Stock upon vesting.

Referenced by the price of 1 transaction in Table I.

F3

Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2025 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting on a one for one basis.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)